Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Retinopati hos premature - visuell funksjon og retinal struktur

9. november 2026 oppdatert av: Erlend Christoffer Sommer Landsend, Oslo University Hospital

Barn behandlet for prematuritetens retinopati - Studie av visuell funksjon og retinal struktur

Children born prematurely may develop a characteristic retinal disease named retinopathy of prematurity (ROP). This disease could lead to retinal detachment and blindness. ROP was traditionally treated with laser, but injection with a medication (A-VEGF) has become more common.

In this study, the researchers will explore whether treatment of ROP affects visual function and retinal development. To explore this, the study group will examine children with ROP (but not treated) with children treated with either laser or injection. The researchers will compare the children's visual functions (e.g. visual acuity and visual field) and their retinas (e.g. central and peripheral retina).

Studieoversikt

Detaljert beskrivelse

Children born prematurely may develop a characteristic retinal disease named retinopathy of prematurity (ROP). The risk of ROP increases with lower gestational age and birth weight of the child. In a child born pre-term the blood vessels in the retina may not be fully developed. New - but unstructured - vessels could grow up from the retina and lead to retinal detachment and blindness. ROP was traditionally treated with laser, but injection with a medication (A-VEGF) into the eye has become more common.

In this study, the researchers aim to explore whether treatment of ROP affects visual function and retinal development. To investigate this, the study group will examine children with ROP (but not treated) with children treated with either laser or injection. The researchers will compare the children's visual functions (e.g. visual acuity and visual field) and their retinas (e.g. central and peripheral retina).

The participants will undergo a comprehensive eye examination, including imaging of the retina, visual field testing, and biometric measurements. Their parents will also answer questions regarding cerebral visual impairment.

Results from the group not treated for ROP will be compared to the treated subjects. Data will also be correlated with non-ocular parameters, such at gestational age, birth weight and brain hemorrhages.

Studietype

Observasjonsmessig

Registrering (Antatt)

140

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Erlend Christoffer Sommer Landsend, M.D., Ph.D.
  • Telefonnummer: 0047 91 50 27 70
  • E-post: erllan@ous-hf.no

Studer Kontakt Backup

  • Navn: Amanda Schjetlein, M.D.
  • Telefonnummer: 0047 91 50 27 70
  • E-post: amasch@ous-hf.no

Studiesteder

    • Oslo
      • Oslo, Oslo, Norge, 0424
        • Oslo University Hospital
        • Ta kontakt med:
          • Amanda Schjetlein, M.D.
          • Telefonnummer: 0047 91 50 27 70
          • E-post: amasch@ous-hf.no
        • Ta kontakt med:
          • Erlend C. S. Landsend, M.D., Ph.D.
          • Telefonnummer: 0047 91 50 27 70
          • E-post: erllan@ous-hf.no

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

6 år til 20 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

  • Group 1: patients treated for ROP with laser
  • Group 2: patients previously diagnosed with ROP but not treated (matched 1:1 with patients in group 1)
  • Group 3: patients treated for ROP with injection of A-VEGF
  • Group 4: patients previously diagnosed with ROP but not treated (matched 1:1 with patients in group 3)

Beskrivelse

Inclusion criteria:

  • Patients treated for ROP with either laser or injection of A-VEGF.
  • Patients previously diagnosed with ROP but not treated for the condition.

Exclusion criteria:

  • Age below six years at date of examination.
  • A developmental level not compatible with performing the study examinations.
  • Patients born or treated outside Norway
  • Known ocular or systemic disease that can give structural or functional changes in the retina.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: CASE_CONTROL
  • Tidsperspektiver: CROSS_SECTIONAL

Kohorter og intervensjoner

Gruppe / Kohort
Laser treated

Subjects treated for ROP with laser of avascular retina

Control laser treated

Control subjects matched with subjects treated with laser

A-VEGF treated

Subjects treated for ROP with intravitreal injection of A-VEGF

Control A-VEGF treated

Control subjects matched with subjects treated with A-VEGF

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Width of the foveal avascular zone
Tidsramme: From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years

Width of the foveal avascular zone in micrometers measured with optical coherence tomography angiography

From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years
Choroidal vascularity
Tidsramme: From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Choroidal vascularity in the macula measured with optical coherence tomography and with choroidal vascularity index in percent

From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.
Retinal nerve fiber layer thickness
Tidsramme: From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Retinal nerve fiber layer thickness in micrometers measured with optical coherence tomography

From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.
Length of persistent avascular retina
Tidsramme: From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Length of persistent avascular retina measured in millimeters using scanning laser ophthalmoscopy and fluorescein angiography

From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.
Width of the visual field
Tidsramme: From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Width of the visual field in degrees measured with Goldmann Perimetry

From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Correlation between cerebral visual impairment and brain hemorrhages
Tidsramme: Neonatal period to time for data collection in the current study

Correlation between scores for cerebral visual impairment at time of the study and brain hemorrhages in neonatal period

Neonatal period to time for data collection in the current study
Visual acuity
Tidsramme: From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Visual acuity measured with LogMAR.

From date of treatment with either laser or A-VEGF until date of examination in the current study, with a maximum of 18 years.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studiestol: Erlend Christoffer Sommer Landsend, M.D., Ph.D., Oslo University Hospital

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. januar 2028

Studiet fullført (Antatt)

1. juni 2029

Datoer for studieregistrering

Først innsendt

19. januar 2026

Først innsendt som oppfylte QC-kriteriene

16. februar 2026

Først lagt ut (Faktiske)

23. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. februar 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

Awaits allowance to share IPD from the Regional committees for medical and health research ethics.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere